Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation

NANot yet recruitingINTERVENTIONAL
Enrollment

735

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2032

Conditions
Endometrial Cancer
Interventions
DIAGNOSTIC_TEST

ENDORISK personalized risk assesment for lymph node metastases in endometrial cancer.

The intervention group are patients receiving a personalized risk on lymph node metastases as predicted by the ENDORISK model, they also receive a treatment plan (hysterectomy + bilateral salpingo-oophorectomy with or without lymph node surgery) based on this personalized risk.

Trial Locations (14)

Unknown

Rijnstate, Arnhem

Slingeland Hospital, Doetinchem

Gelderse Vallei, Ede

Canisius Wilhelmina Ziekenhuis (CWZ), Nijmegen

Streekziekenhuis Koningin Beatrix, Winterswijk

Jeroen Bosch Hospital, 's-Hertogenbosch

Amphia, Breda

Catharina Hospital, Eindhoven

St. Anna Hospital, Geldrop

Elkerliek Hospital, Helmond

Elisabeth-Tweesteden Hospital, Tilburg

Bernhoven Hospital, Uden

Maxima Medical Center, Veldhoven

6525GA

Radboudumc, Nijmegen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Elisabeth-TweeSteden Ziekenhuis

OTHER

collaborator

Amphia Hospital

OTHER

collaborator

Catharina Ziekenhuis Eindhoven

OTHER

collaborator

Elkerliek Hospital

OTHER

collaborator

St. Anna Ziekenhuis, Geldrop, Netherlands

OTHER

collaborator

Jeroen Bosch Ziekenhuis, s'-Hertogenbosch

UNKNOWN

collaborator

Rijnstate Hospital

OTHER

collaborator

Canisius Wilhelmina Ziekenhuis (CWZ)

UNKNOWN

collaborator

Maxima Medical Center

OTHER

collaborator

Bernhoven Hospital

OTHER

collaborator

Maas Hospital Pantein

OTHER

collaborator

Slingeland Hospital

OTHER

collaborator

Streekziekenhuis Koningin Beatrix

UNKNOWN

collaborator

Gelderse Vallei Hospital

OTHER

collaborator

Comprehensive Cancer Centre The Netherlands

OTHER

collaborator

Stichting PAMM

UNKNOWN

lead

Radboud University Medical Center

OTHER